help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-1084
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
91/12/5069    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Birkenfeld, A. L.
Right arrow Articles by Jordan, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Birkenfeld, A. L.
Right arrow Articles by Jordan, J.
Related Collections
Right arrow Cardiovascular Endocrinology
Right arrow Metabolism
The Journal of Clinical Endocrinology & Metabolism Vol. 91, No. 12 5069-5075
Copyright © 2006 by The Endocrine Society

ß-Adrenergic and Atrial Natriuretic Peptide Interactions on Human Cardiovascular and Metabolic Regulation

Andreas L. Birkenfeld, Michael Boschmann, Cedric Moro, Frauke Adams, Karsten Heusser, Jens Tank, André Diedrich, Christoph Schroeder, Gabi Franke, Michel Berlan, Friedrich C. Luft, Max Lafontan and Jens Jordan

Franz-Volhard Clinical Research Center (A.L.B., M.Bo., F.A., K.H., J.T., C.S., G.F., F.C.L., J.J.), Charité Campus Buch and HELIOS Klinikum, 13125 Berlin, Germany; Institut National de la Santé et de la Recherche Médicale Unit 586 (C.M., M.Be., M.L.), Institut Louis Bugnard, Université Paul Sabatier, Hôpital Rangueil, 31403 Toulouse, France; and Autonomic Dysfunction Center (A.D.), Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical School, Nashville, Tennessee 37232

Address all correspondence and requests for reprints to: Jens Jordan, M.D., Franz-Volhard Clinical Research Center, Haus 129, Charité Campus Buch, Wiltbergstr. 50, 13125 Berlin, Germany. E-mail: jordan{at}fvk.charite-buch.de.

Context: Atrial natriuretic peptide (ANP) has well-known cardiovascular effects and modifies lipid and carbohydrate metabolism in humans.

Objective: The objective of the study was to determine the metabolic and cardiovascular interaction of ß-adrenergic receptors and ANP.

Design: This was a crossover study, conducted 2004–2005.

Setting: The study was conducted at an academic clinical research center.

Patients: Patients included 10 healthy young male subjects (body mass index 24 ± 1 kg/m2).

Intervention: We infused iv incremental ANP doses (6.25, 12.5, and 25 ng/kg·min) with and without propranolol (0.20 mg/kg in divided doses followed by 0.033 mg/kg·h infusion). Metabolism was monitored through venous blood sampling, im, and sc microdialysis and indirect calorimetry. Cardiovascular changes were monitored by continuous electrocardiogram and beat-by-beat blood pressure recordings.

Main Outcome Measures: Venous nonesterified fatty acid, glycerol, glucose, and insulin; and microdialysate glucose, glycerol, lactate, and pyruvate were measured.

Results: ANP increased heart rate dose dependently. ß-Adrenergic receptor blockade abolished the response. ANP elicited a dose-dependent increase in serum nonesterified fatty acid and glycerol concentrations. The response was not suppressed with propranolol. Venous glucose and insulin concentrations increased with ANP, both without or with propranolol. ANP induced lipid mobilization in sc adipose tissue. In skeletal muscle, microdialysate lactate increased, whereas the lactate to pyruvate ratio decreased, both with and without propranolol. Higher ANP doses increased lipid oxidation, whereas energy expenditure remained unchanged. Propranolol tended to attenuate the increase in lipid oxidation.

Conclusions: Selected cardiovascular ANP effects are at least partly mediated by ß-adrenergic receptor stimulation. ANP-induced changes in lipid mobilization and glycolysis are mediated by another mechanism, presumably stimulation of natriuretic peptide receptors, whereas substrate oxidation might be modulated through adrenergic mechanisms.




This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. Moro, F. Pillard, I. de Glisezinski, F. Crampes, C. Thalamas, I. Harant, M.-A. Marques, M. Lafontan, and M. Berlan
Atrial natriuretic peptide contribution to lipid mobilization and utilization during head-down bed rest in humans
Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R612 - R617.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society